The new-generation proteasome inhibitor oprozomib increases the sensitivity of cervical cancer cells to cisplatin-induced apoptosis.
Li QZ, Sun LP, Shi HY, Chen Y, Shen H.
J Biol Regul Homeost Agents · journal article · DOI 10.23812/20-504-a PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för oprozomib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
21 träffarOral Proteasomal Inhibitors Ixazomib, Oprozomib, and Delanzomib Upregulate the Function of Organic Anion Transporter 3 (OAT3): Implications in OAT3-Mediated Drug-Drug Interactions.
Fan Y, Liang Z, Zhang J, You G.
Pharmaceutics · research-article; journal article · DOI 10.3390/pharmaceutics13030314ONX0912, a selective oral proteasome inhibitor, triggering mitochondrial apoptosis and mitophagy in liver cancer.
Wu M, Chen P, Liu F, Lv B, Ge M, Jiang P, Xu W, Liu X, Yang D.
Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2021.02.037Prolonged unfolded protein reaction is involved in the induction of chronic myeloid leukemia cell death upon oprozomib treatment.
Wang F, Wang X, Li N, Liu J, Zhang L, Hui L, Feng A, Wang Z, Wang Y.
Cancer Sci · research-article; journal article · DOI 10.1111/cas.14696The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms.
Caputi FF, Di Cesare Mannelli L, Rullo L, Micheli L, Stamatakos S, Posa L, Ghelardini C, Romualdi P, Candeletti S.
Biochem Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bcp.2020.114255Overexpression of immunoproteasome low-molecular-mass polypeptide 7 and inhibiting role of next-generation proteasome inhibitor ONX 0912 on cell growth in glioma.
Min L, Zeng X, Li B, Tao B, Shi J, Zhang W, Sun Q, Jing C, Wang X.
Neuroreport · research support, non-u.s. gov't; journal article · DOI 10.1097/wnr.0000000000001320An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro.
Zhu H, Wang T, Xin Z, Zhan Y, Gu G, Li X, Wang X, Yang S, Liu C.
Acta Biochim Biophys Sin (Shanghai) · journal article · DOI 10.1093/abbs/gmz093Oprozomib in patients with newly diagnosed multiple myeloma.
Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P.
Blood Cancer J · letter; brief-report; research support, non-u.s. gov't · DOI 10.1038/s41408-019-0232-6Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Hari P, Paba-Prada CE, Voorhees PM, Frye J, Chang YL, Moreau P, Zonder J, Boccia R, Shain KH.
Leuk Res · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1016/j.leukres.2019.106172A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.
Ghobrial IM, Vij R, Siegel D, Badros A, Kaufman J, Raje N, Jakubowiak A, Savona MR, Obreja M, Berdeja JG.
Clin Cancer Res · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-18-3728Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Shah J, Usmani S, Stadtmauer EA, Rifkin RM, Berenson JR, Berdeja JG, Lyons RM, Klippel Z, Chang YL, Niesvizky R.
Clin Lymphoma Myeloma Leuk · research support, non-u.s. gov't; journal article · DOI 10.1016/j.clml.2019.05.017Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Ou Y, Xu Y, Gore L, Harvey RD, Mita A, Papadopoulos KP, Wang Z, Cutler RE, Pinchasik DE, Tsimberidou AM.
Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1111/bcp.13817Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.
Shi Y, Bieerkehazhi S, Ma H.
Int J Clin Exp Pathol · research-article; journal articleIn Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s.
Wang Z, Fang Y, Teague J, Wong H, Morisseau C, Hammock BD, Rock DA, Wang Z.
Drug Metab Dispos · research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/dmd.117.075226Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex).
Sanchez E, Li M, Wang CS, Tang G, Gillespie A, Chen H, Berenson JR.
Leuk Res · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.leukres.2017.03.002Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
Vandewynckel YP, Coucke C, Laukens D, Devisscher L, Paridaens A, Bogaerts E, Vandierendonck A, Raevens S, Verhelst X, Van Steenkiste C, Libbrecht L, Geerts A, Van Vlierberghe H.
Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.9222A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
Infante JR, Mendelson DS, Burris HA, Bendell JC, Tolcher AW, Gordon MS, Gillenwater HH, Arastu-Kapur S, Wong HL, Papadopoulos KP.
Invest New Drugs · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s10637-016-0327-xCarfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.
Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE.
Clin Cancer Res · research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-12-1213The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN.
Leukemia · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/leu.2012.183A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.
Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC.
Blood · research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/blood-2010-04-276626Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Parlati F, Ring E, Shenk KD, Shields J, Shwonek PJ, Stanton T, Sun CM, Sylvain C, Woo TM, Yang J.
J Med Chem · journal article · DOI 10.1021/jm801329v